The First Affiliated Hospital of Shandong First Medical University (Shandong Qianfoshan Hospital)
Jinan, Shandong, 250014, China
NCT Number: NCT07284043
MT1013 is a first-in-class dual-target agonist.This study is being conducted to determine the mass balance and routes of excretion of total radioactivity after the dose of [14C] MT1013.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Phase 1
Jinan, Shandong, 250014, China
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
[14C] MT1013/MT1013 Injection
Time frame: Day 1 to Day 91.
Time frame: Day 1 to Day 91.
Time frame: About 13 weeks.
Time frame: About 13 weeks.
Shaanxi Micot Pharmaceutical Technology Co., Ltd.
Industry
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.